Option And License Agreement Sample Contracts

Knight Knox Development Corp. – Material and Data Transfer, Option and License Agreement (March 21st, 2018)

THIS MATERIAL AND DATA TRANSFER, OPTION AND LICENSE AGREEMENT (this "Agreement") entered into on this December 20, 2017 (the "Signature Date") by and between NEOMED Institute, a not-for-profit corporation established under the Not-for-Profit Corporations Act (Canada), having an address at 7171 Frederick-Banting, Saint-Laurent, Quebec H4S 1Z9, Canada ("NEOMED"), and Artelo Biosciences, Inc., a Nevada corporation, having an address at 888 Prospect Street, Suite 210, La Jolla, California 92037, U.S.A. ("Artelo") shall be effective as of the Effective Date (as defined in Section 1.9 below). Each of NEOMED and Artelo may be referred to herein as a "Party", or jointly as the "Parties".

GLOBAL DEVELOPMENT, OPTION AND LICENSE AGREEMENT Between NESTEC LTD. And CODEXIS, INC. (March 15th, 2018)

This GLOBAL DEVELOPMENT, OPTION AND LICENSE AGREEMENT (this "Agreement") is made as of October 12, 2017 (the "Effective Date"), by and between NESTEC LTD., a limited company organized and existing under the laws of Switzerland, having an office located at Avenue Nestle 55, 1800 Vevey, Switzerland ("NHSc"), and CODEXIS, INC., a corporation incorporated and existing under the laws of the State of Delaware, having an office located at 200 Penobscot Drive, Redwood City, CA 94063, USA ("Codexis"). NHSc and Codexis are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Avalanche Biotechnologies, Inc. – Amendment to Collaboration, Option and License Agreement (March 6th, 2018)

This Amendment ("Amendment") is entered into as of January 25, 2018 (the "Amendment Effective Date"), by and between Adverum Biotechnologies, Inc., a Delaware corporation having an address at 1035 O'Brien Drive, Menlo Park, CA 94025 ("Adverum"), and Editas Medicine, Inc., a Delaware corporation having an address at 11 Hurley St., Cambridge, MA 02141 ("Editas") and amends that certain Collaboration, Option and License Agreement, dated August 8, 2016, by and between Adverum and Editas (the "Agreement"). Adverum and Editas may be referred to herein individually as a "Party" and collectively as the "Parties."

Isis Pharmaceuticals, Inc. – Amended and Restated Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement Between Ionis Pharmaceuticals, Inc. And Biogen MA Inc. (February 28th, 2018)

This AMENDED AND RESTATED STRATEGIC NEUROLOGY DRUG DISCOVERY AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT (the "Agreement") is entered into as of the 20th day of October, 2017 (the "Amendment Date") by and between Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 ("Ionis"), and Biogen MA Inc., a Massachusetts corporation, having its principal place of business at 14 Cambridge Center, Cambridge, MA 02142 ("Biogen"). Biogen and Ionis each may be referred to herein individually as a "Party" or collectively as the "Parties." Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement.

Isis Pharmaceuticals, Inc. – Research Collaboration, Option and License Agreement Between Ionis Pharmaceuticals, Inc. And Biogen MA Inc. (February 28th, 2018)

This RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT (this "Agreement") is entered into as of the 19th day of December 2017 (the "Effective Date") by and between Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 ("Ionis"), and Biogen MA Inc., a Massachusetts corporation, having its principal place of business at 225 Binney Street, Cambridge, MA 02142 ("Biogen"). Biogen and Ionis each may be referred to herein individually as a "Party" or collectively as the "Parties." Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement.

Ultragenyx Pharmaceutical Inc. – Option and License Agreement (February 21st, 2018)

This OPTION AND LICENSE AGREEMENT ("Agreement") is entered into as of March 10, 2015 (the "Execution Date"), with effectiveness as of February 18, 2014 (the "Effective Date"), by and between REGENXBIO Inc., a limited liability company organized under the laws of the State of Delaware, with offices at 1701 Pennsylvania Avenue, NW, Suite 900, Washington, DC 20006 ("Licensor"), and Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 ("Licensee"). Licensor and Licensee are hereinafter referred to individually as a "Party" and collectively as the "Parties."

Arcus Biosciences, Inc. – Confidential Treatment Requested Option and License Agreement (February 16th, 2018)

THIS OPTION AND LICENSE AGREEMENT (Agreement) is made and entered into effective as of September 19, 2017 (the Effective Date), by and between ARCUS BIOSCIENCES, INC., a company organized under the laws of State of Delaware, U.S.A., having a business address at 3928 Point Eden Way, Hayward, CA 94545, U.S.A. (Arcus), and TAIHO PHARMACEUTICAL CO., LTD., a corporation organized under the laws of Japan, having a business address at 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan (TAIHO).

To the Strategic Collaboration, Option and License Agreement (February 15th, 2018)

This Amendment No. 1 to the Strategic Collaboration, Option and License Agreement, dated October 26, 2015, between Vertex Pharmaceuticals Incorporated (" Vertex Parent ") and Vertex Pharmaceuticals (Europe) Limited (" Vertex UK " and together with Vertex Parent, " Vertex "), on the one hand, and CRISPR Therapeutics AG (" CRISPR AG "), CRISPR Therapeutics, Inc. (" CRISPR Inc. "), CRISPR Therapeutics Limited (" CRISPR UK ") and TRACR Hematology Ltd (" Tracr " and together with CRISPR AG, CRISPR Inc. and CRISPR UK " CRISPR "), on the other hand (this " Amendment ") is entered into as of this 12th day of December, 2017 (the " Amendment Effective Date ") by and between Vertex and CRISPR. Capitalized terms used and not defined herein have their respective meanings set forth in the Agreement (as defined below).

Arcus Biosciences, Inc. – Confidential Treatment Requested Option and License Agreement (January 19th, 2018)

THIS OPTION AND LICENSE AGREEMENT (Agreement) is made and entered into effective as of September 19, 2017 (the Effective Date), by and between ARCUS BIOSCIENCES, INC., a company organized under the laws of State of Delaware, U.S.A., having a business address at 3928 Point Eden Way, Hayward, CA 94545, U.S.A. (Arcus), and TAIHO PHARMACEUTICAL CO., LTD., a corporation organized under the laws of Japan, having a business address at 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan (TAIHO).

Knight Knox Development Corp. – Confidential Treatment Requested Confidential Portions of This Document Have Been Redacted and Have Been Separately Filed With the Securities and Exchange Commission. Information That Was Omitted in the Edgar Version Has Been Noted in This Document With a Placeholder Identified by the Mark "[***]". Material and Data Transfer, Option and License Agreement (January 16th, 2018)

THIS MATERIAL AND DATA TRANSFER, OPTION AND LICENSE AGREEMENT (this "Agreement") entered into on this December 20, 2017 (the "Signature Date") by and between NEOMED Institute, a not-for-profit corporation established under the Not-for-Profit Corporations Act (Canada), having an address at 7171 Frederick-Banting, Saint-Laurent, Quebec H4S 1Z9, Canada ("NEOMED"), and Artelo Biosciences, Inc., a Nevada corporation, having an address at 888 Prospect Street, Suite 210, La Jolla, California 92037, U.S.A. ("Artelo") shall be effective as of the Effective Date (as defined in Section 1.9 below). Each of NEOMED and Artelo may be referred to herein as a "Party", or jointly as the "Parties".

Knight Knox Development Corp. – Material and Data Transfer, Option and License Agreement (December 22nd, 2017)

THIS MATERIAL AND DATA TRANSFER, OPTION AND LICENSE AGREEMENT (this "Agreement") entered into on this December 20, 2017 (the "Signature Date") by and between NEOMED Institute, a not-for-profit corporation established under the Not-for-Profit Corporations Act (Canada), having an address at 7171 Frederick-Banting, Saint-Laurent, Quebec H4S 1Z9, Canada ("NEOMED"), and Artelo Biosciences, Inc., a Nevada corporation, having an address at 888 Prospect Street, Suite 210, La Jolla, California 92037, U.S.A. ("Artelo") shall be effective as of the Effective Date (as defined in Section 1.9 below). Each of NEOMED and Artelo may be referred to herein as a "Party", or jointly as the "Parties".

CRISPR Therapeutics AG – Amendment No. 1 to the Strategic Collaboration, Option and License Agreement (December 18th, 2017)

This Amendment No. 1 to the Strategic Collaboration, Option and License Agreement, dated October 26, 2015, between Vertex Pharmaceuticals Incorporated (Vertex Parent) and Vertex Pharmaceuticals (Europe) Limited (Vertex UK and together with Vertex Parent, Vertex), on the one hand, and CRISPR Therapeutics AG (CRISPR AG), CRISPR Therapeutics, Inc. (CRISPR Inc.), CRISPR Therapeutics Limited (CRISPR UK) and TRACR Hematology Ltd (Tracr and together with CRISPR AG, CRISPR Inc. and CRISPR UK CRISPR), on the other hand (this Amendment) is entered into as of this 12th day of December, 2017 (the Amendment Effective Date) by and between Vertex and CRISPR. Capitalized terms used and not defined herein have their respective meanings set forth in the Agreement (as defined below).

Arcus Biosciences, Inc. – Confidential Treatment Requested Option and License Agreement (December 15th, 2017)

THIS OPTION AND LICENSE AGREEMENT (Agreement) is made and entered into effective as of September 19, 2017 (the Effective Date), by and between ARCUS BIOSCIENCES, INC., a company organized under the laws of State of Delaware, U.S.A., having a business address at 3928 Point Eden Way, Hayward, CA 94545, U.S.A. (Arcus), and TAIHO PHARMACEUTICAL CO., LTD., a corporation organized under the laws of Japan, having a business address at 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan (TAIHO).

Monopar Therapeutics – VALIDIVE(r) OPTION AND LICENSE AGREEMENT BY AND BETWEEN MONOPAR THERAPEUTICS INC. And (November 9th, 2017)

THIS OPTION AND LICENSE AGREEMENT (together with any Schedules attached hereto, this "Agreement") is made and entered into as of June 17, 2016 (the "Effective Date"), by and between Monopar Therapeutics Inc., a Delaware corporation located at 598 Rockefeller Rd, Lake Forest, Illinois 60201, United States of America ("Monopar"), and Onxeo S.A., a French societe anonyme a Conseil d'administration located at 49, boulevard du General Martial Valin, 75015 Paris, France ("Onxeo"). Monopar and Onxeo are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Max-1 Acquisition Corp – RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT by and Between EXICURE, INC. And PURDUE PHARMA L.P. (November 7th, 2017)

This RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT (this "Agreement") is entered into as of December 2nd, 2016 (the "Effective Date") by and between EXICURE, INC., a Delaware corporation having an address at 8045 Lamon Ave, Skokie, Illinois 60077, United States of America ("Licensor"), and PURDUE PHARMA L.P., a Delaware limited partnership having an address at One Stamford Forum, 201 Tresser Boulevard, Stamford, Connecticut 06901, United States of America ("Licensee"). Licensor and Licensee are sometimes referred to individually as a "Party" and collectively as the "Parties."

Arsanis, Inc. – Option and License Agreement (October 20th, 2017)

THIS OPTION AND LICENSE AGREEMENT (the Agreement) is made effective as of February 27, 2017 (the Effective Date), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (Adimab), and ARSANIS INC., a Delaware corporation having an address at 890 Winter Street, Suite 230, Waltham, MA 02451-1472 (Arsanis).

Arsanis, Inc. – Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. AMENDMENT NO. 1 to the OPTION AND LICENSE AGREEMENT (October 20th, 2017)
Arsanis, Inc. – Option and License Agreement (September 20th, 2017)

THIS OPTION AND LICENSE AGREEMENT (the Agreement) is made effective as of February 27, 2017 (the Effective Date), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (Adimab), and ARSANIS INC., a Delaware corporation having an address at 890 Winter Street, Suite 230, Waltham, MA 02451-1472 (Arsanis).

Arsanis, Inc. – Option and License Agreement (August 10th, 2017)

THIS OPTION AND LICENSE AGREEMENT (the Agreement) is made effective as of February 27, 2017 (the Effective Date), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (Adimab), and ARSANIS INC., a Delaware corporation having an address at 890 Winter Street, Suite 230, Waltham, MA 02451-1472 (Arsanis).

Isis Pharmaceuticals, Inc. – Strategic Collaboration, Option and License Agreement (May 9th, 2017)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (the "Agreement") is entered into as of the 5th day of January, 2017 (the "Execution Date") by and between Akcea Therapeutics, Inc., a Delaware corporation, having its principal place of business at 55 Cambridge Parkway, Cambridge, MA 02142 USA, together with each of Akcea's Affiliates ("Akcea"), andNovartis Pharma AG, a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland ("Novartis"). Novartis and Akcea each may be referred to herein individually as a "Party" or collectively as the "Parties." Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement. As of the Effective Date, Akcea is a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. ("Ionis") and therefore Akcea and Ionis are Affiliates.

Akcea Therapeutics, Inc. – Strategic Collaboration, Option and License Agreement Between Akcea Therapeutics, Inc. And Novartis Pharma Ag (April 10th, 2017)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (the Agreement) is entered into as of the 5th day of January, 2017 (the Execution Date) by and between AKCEA THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 55 Cambridge Parkway, Cambridge, MA 02142 USA, together with each of Akceas Affiliates (Akcea), and NOVARTIS PHARMA AG, a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland (Novartis). Novartis and Akcea each may be referred to herein individually as a Party or collectively as the Parties. Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement. As of the Effective Date, Akcea is a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (Ionis) and therefore Akcea and Ionis are Affiliates.

Avalanche Biotechnologies, Inc. – Collaboration, Option and License Agreement (April 5th, 2017)

THIS COLLABORATION, OPTION AND LICENSE AGREEMENT (the Agreement) is entered into as of August 8, 2016 (Effective Date), by and between ADVERUM BIOTECHNOLOGIES, INC., a Delaware corporation having an address at 1035 OBrien Drive, Menlo Park, CA 94025 (Adverum), and EDITAS MEDICINE, INC., a Delaware corporation having an address at 300 Third Street, Cambridge, MA 02142 (Editas). Adverum and Editas may be referred to herein individually as a Party and collectively as the Parties.

Akcea Therapeutics, Inc. – Strategic Collaboration, Option and License Agreement Between Akcea Therapeutics, Inc. And Novartis Pharma Ag (March 27th, 2017)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (the Agreement) is entered into as of the 5th day of January, 2017 (the Execution Date) by and between AKCEA THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 55 Cambridge Parkway, Cambridge, MA 02142 USA, together with each of Akceas Affiliates (Akcea), and NOVARTIS PHARMA AG, a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland (Novartis). Novartis and Akcea each may be referred to herein individually as a Party or collectively as the Parties. Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement. As of the Effective Date, Akcea is a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (Ionis) and therefore Akcea and Ionis are Affiliates.

Chimerix Inc. – Patent Option and License Agreement (March 2nd, 2017)

This Agreement is entered into on May 24, 2006 ("EFFECTIVE DATE"), between The Regents of the University of Michigan, a constitutional corporation of the State of Michigan ("MICHIGAN") located at Office of Technology Transfer, 3003 S. State Street, Suite 2071, Ann Arbor, MI 48109-1280, and Chimerix, Inc., a Delaware corporation ("COMPANY"), located at 5007 Southpark Drive, Suite 200, Durham, NC 27713.

Akcea Therapeutics, Inc. – Strategic Collaboration, Option and License Agreement Between Akcea Therapeutics, Inc. And Novartis Pharma Ag (February 13th, 2017)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (the Agreement) is entered into as of the 5th day of January, 2017 (the Execution Date) by and between AKCEA THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 55 Cambridge Parkway, Cambridge, MA 02142 USA, together with each of Akceas Affiliates (Akcea), and NOVARTIS PHARMA AG, a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland (Novartis). Novartis and Akcea each may be referred to herein individually as a Party or collectively as the Parties. Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement. As of the Effective Date, Akcea is a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (Ionis) and therefore Akcea and Ionis are Affiliates.

Ocular Therapeutix, Inc – Collaboration, Option and License Agreement Between Ocular Therapeutix, Inc. And Regeneron Pharmaceuticals, Inc. (November 9th, 2016)

THIS COLLABORATION, OPTION AND LICENSE AGREEMENT (this Agreement) is made and entered into, effective as of October 10, 2016 (the Effective Date), by and between Ocular Therapeutix, Inc., a corporation organized under the laws of Delaware and having an address at 36 Crosby Drive, Suite 101, Bedford, Massachusetts 01730 (Collaborator), and Regeneron Pharmaceuticals, Inc., a corporation organized under the laws of New York and having an address at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (Regeneron). Collaborator and Regeneron are sometimes referred to herein individually as a Party and collectively as the Parties.

Avalanche Biotechnologies, Inc. – Collaboration, Option and License Agreement (November 8th, 2016)

This Collaboration, Option and License Agreement (the "Agreement") is entered into as of August 8, 2016 ("Effective Date"), by and between Adverum Biotechnologies, Inc., a Delaware corporation having an address at 1035 O'Brien Drive, Menlo Park, CA 94025 ("Adverum"), and Editas Medicine, Inc., a Delaware corporation having an address at 300 Third Street, Cambridge, MA 02142 ("Editas"). Adverum and Editas may be referred to herein individually as a "Party" and collectively as the "Parties."

CRISPR Therapeutics AG – Strategic Collaboration, Option and License Agreement Between Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals (Europe) Limited and Crispr Therapeutics Ag Crispr Therapeutics Limited Crispr Therapeutics, Inc. Tracr Hematology Ltd. (October 7th, 2016)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (this Agreement) is entered into as of October 26, 2015 (the Effective Date) by and between, on the one hand, VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of The Commonwealth of Massachusetts (Vertex Parent), and VERTEX PHARMACEUTICALS (EUROPE) LIMITED, a private limited liability company organized under the laws of England and Wales (Vertex UK and, together with Vertex Parent, Vertex) and, on the other hand, CRISPR THERAPEUTICS AG, a corporation organized under the laws of Switzerland (CRISPR AG), CRISPR THERAPEUTICS, INC., a corporation organized under the laws of the state of Delaware (CRISPR Inc.), CRISPR THERAPEUTICS LIMITED, a corporation organized under the laws of England and Wales (CRISPR UK) and TRACR HEMATOLOGY LTD, a UK limited company (Tracr and together with CRISPR AG, CRISPR Inc. and CRISPR UK CRISPR). Vertex and CRISPR each may be referred to herein individually as a P

CRISPR Therapeutics AG – Strategic Collaboration, Option and License Agreement Between Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals (Europe) Limited and Crispr Therapeutics Ag Crispr Therapeutics Limited Crispr Therapeutics, Inc. Tracr Hematology Ltd. (August 19th, 2016)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (this Agreement) is entered into as of October 26, 2015 (the Effective Date) by and between, on the one hand, VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of The Commonwealth of Massachusetts (Vertex Parent), and VERTEX PHARMACEUTICALS (EUROPE) LIMITED, a private limited liability company organized under the laws of England and Wales (Vertex UK and, together with Vertex Parent, Vertex) and, on the other hand, CRISPR THERAPEUTICS AG, a corporation organized under the laws of Switzerland (CRISPR AG), CRISPR THERAPEUTICS, INC., a corporation organized under the laws of the state of Delaware (CRISPR Inc.), CRISPR THERAPEUTICS LIMITED, a corporation organized under the laws of England and Wales (CRISPR UK) and TRACR HEMATOLOGY LTD, a UK limited company (Tracr and together with CRISPR AG, CRISPR Inc. and CRISPR UK CRISPR). Vertex and CRISPR each may be referred to herein individually as a P

CRISPR Therapeutics AG – Strategic Collaboration, Option and License Agreement (July 8th, 2016)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (this Agreement) is entered into as of October 26, 2015 (the Effective Date) by and between, on the one hand, VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of The Commonwealth of Massachusetts (Vertex Parent), and VERTEX PHARMACEUTICALS (EUROPE) LIMITED, a private limited liability company organized under the laws of England and Wales (Vertex UK and, together with Vertex Parent, Vertex) and, on the other hand, CRISPR THERAPEUTICS AG, a corporation organized under the laws of Switzerland (CRISPR AG), CRISPR THERAPEUTICS, INC., a corporation organized under the laws of the state of Delaware (CRISPR Inc.), CRISPR THERAPEUTICS LIMITED, a corporation organized under the laws of England and Wales (CRISPR UK) and TRACR HEMATOLOGY LTD, a UK limited company (Tracr and together with CRISPR AG, CRISPR Inc. and CRISPR UK CRISPR). Vertex and CRISPR each may be referred to herein individually as a P

Cempra Inc. – Option and License Agreement (June 17th, 2016)

This OPTION AND LICENSE AGREEMENT (the Agreement) is entered into as of January 29, 2016 (the Effective Date) by and between Cempra Pharmaceuticals, Inc., a Delaware corporation having an address at 6320 Quadrangle Dr. #360, Chapel Hill, NC 27517 (Cempra), and Macrolide Pharmaceuticals, Inc., a Delaware corporation having an address at 480 Arsenal St., Suite 130, Watertown, MA 02472 (MP). MP and Cempra may be referred to herein individually as a Party or collectively, as the Parties.

Acucela Inc. – Option and License Agreement (May 10th, 2016)

THIS OPTION AND LICENSE AGREEMENT ("Agreement") is made and entered into effective as of March 16, 2016 (the "Effective Date"), by and between ACUCELA INC., a corporation organized under the laws of the State of Washington, USA, having a business address at 1301 Second Avenue, Suite 4200, Seattle, Washington 98101-3805, USA ("Acucela"), and YOUHEALTH EYETECH, INC., a corporation organized under the laws of the State of Delaware, USA, having a business address at 10769 Cherry Hill Drive, San Diego, California 92130, USA ("YouHealth"). In addition, YouHealth's parent company, GUANGZHOU KANG RUI BIOLOGICAL PHARMACEUTICAL TECHNOLOGY CO., LTD., a Chinese company, having a business address at Rui Hou Building F, 6th Floor Guangzhou International Business Incubator Science Park, Guangzhou, 510663 China ("Kangrui"), is signing this Agreement as guarantor of YouHealth's performance of its obligations hereunder and hereby agrees to be bound by the terms of this Agreement to the same extent as Y

Cempra Inc. – Option and License Agreement (February 25th, 2016)

This Option and License Agreement (the "Agreement") is entered into as of January 29, 2016 (the "Effective Date") by and between Cempra Pharmaceuticals, Inc., a Delaware corporation having an address at 6320 Quadrangle Dr. #360, Chapel Hill, NC 27517 ("Cempra"), and Macrolide Pharmaceuticals, Inc., a Delaware corporation having an address at 480 Arsenal St., Suite 130, Watertown, MA 02472 ("MP"). MP and Cempra may be referred to herein individually as a "Party" or collectively, as the "Parties."

Strategic Collaboration, Option and License Agreement (February 16th, 2016)

This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (this "Agreement") is entered into as of October 26, 2015 (the "Effective Date") by and between, on the one hand, VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of The Commonwealth of Massachusetts ("Vertex Parent"), and VERTEX PHARMACEUTICALS (EUROPE) LIMITED, a private limited liability company organized under the laws of England and Wales ("Vertex UK" and, together with Vertex Parent, "Vertex") and, on the other hand, CRISPR THERAPEUTICS AG, a corporation organized under the laws of Switzerland ("CRISPR AG"), CRISPR THERAPEUTICS, INC., a corporation organized under the laws of the state of Delaware ("CRISPR Inc."), CRISPR THERAPEUTICS LIMITED, a corporation organized under the laws of England and Wales ("CRISPR UK") and TRACR HEMATOLOGY LTD, a UK limited company ("Tracr" and together with CRISPR AG, CRISPR Inc. and CRISPR UK "CRISPR"). Vertex and CRISPR each may be referred to here

Bavarian Nordic A/S / ADR – Option and License Agreement (January 12th, 2016)

THIS OPTION AND LICENSE AGREEMENT (the Agreement) is made and entered into effective as of 03 March, 2015 (the Effective Date) by and among BAVARIAN NORDIC A/S, a Danish corporation having its principal place of business at Hejreskovvej 10A, DK-3490 Kvistgaard, Denmark (BN) and BAVARIAN NORDIC INC., BNs wholly owned subsidiary, which is a Delaware corporation having its principal place of business at 2425 Garcia Avenue, Mountain View, CA 94043, USA (BNInc), on the one hand, and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 USA (BMS), on the other hand. BN and BMS are sometimes referred to herein individually as a Party and collectively as the Parties. BNInc shall be considered a Party and one of the Parties, in each case jointly with BN, only with respect to the BNInc Provisions and shall have no other rights, obligations or liabilities under this Agreement other than as set out in the BNInc Provisions.